Navigation Links
Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial
Date:6/23/2008

NAGOYA, Japan, June 23 /PRNewswire/ -- Although previous studies suggest that orthokeratology contact lens wear slows the axial length growth of the eye in children with progressing myopia, some limitations in the methodology employed have been evident. Using a rigorous study design and precise optical measuring instruments, Menicon Co., Ltd. and the Novovision Clinic in Madrid are undertaking the Myopia Control with Orthokeratology contact lenses in Spain (MCOS) study to compare the axial length growth between white European myopic children wearing orthokeratology contact lenses (OK) and distance single-vision spectacles (SP) over a 2-year period. In this prospective, single-centre clinical trial, sixty-two subjects 6 to 12 years of age, and with myopia of -0.75 to -4.00 D and astigmatism < =1.00 D were randomly allocated wear OK or SP correction. Measurements of axial length (using partial coherence interferometry, Zeiss IOLMaster), anterior chamber depth, corneal topography, cycloplegic refraction and visual acuity are being performed at 6-month intervals. To date, no subjects have withdrawn from the study, no adverse events were evident and no contact lens fitting modifications were required in the OK group. The MCOS study offers a number of notable features: a prospective design; well matched samples and high resolution ocular biometry measures, which collectively should elucidate whether OK contact lens wear is a feasible method of myopia control.

"The MCOS study aims, using a rigorous study design and precise optical measuring instruments, at elucidating whether orthokeratology lens wear slows the axial length growth of the eye in children with progressing myopia. This study is of special relevance taking into account that the prevalence of myopia has increased substantially over recent decades and now is approaching 10-25% and 60-80% in industrialized societies of the West and East, respectively," commented Dr. Jacinto Santodomingo, Global Professional Relations Manager for Menicon Co., Ltd.

"We have been fitting orthokeratology lenses in our clinic for several years, during which we observed that myopia tended to progress less in children wearing orthokeratology lenses compared to children wearing other modalities of visual correction. We are delighted to participate in this unique clinical trial, which should prove whether we are correct about our preliminary observations," added Mr. Cesar Villa, Director of Optometry at Novovision.

About Menicon:

Menicon Co., Ltd. (http://www.menicon.com), founded by Mr. Kyoichi Tanaka in 1951, is Japan's first and largest contact lens manufacturer, and now is represented in over 30 countries. Menicon is a manufacturer dedicated to all areas of soft and GP contact lens related businesses including material development, lens designing, and manufacturing of contact lenses and care solutions. Menicon is a world-leader in the development of hyper-Dk GP (Menicon Z) and soft contact lenses (Menicon PremiO).

Contact:

Toshio Matsushima

Global Business Operations

Menicon Co., Ltd.

Phone: +81-52-937-5021

Fax: +81-52-935-1121

E-mail: matsushima@menicon-net.co.jp

URL: http://www.menicon.com


'/>"/>
SOURCE Menicon Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
5. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
6. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
9. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
10. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):